Literature DB >> 34559471

Using health check data to investigate cognitive function in Aboriginal and Torres Strait Islanders living with diabetes in the Torres Strait, Australia.

Fintan Thompson1, Linton R Harriss1,2, Sarah Russell2,3, Sean Taylor4, Lucette A Cysique5, Edward Strivens2,3, Paul Maruff6, Robyn McDermott7.   

Abstract

BACKGROUND: Type 2 Diabetes (T2DM) has a subtle deleterious effect on cognition and imposes a higher lifetime risk of cognitive impairment and dementia. In populations where both T2DM and dementia are highly prevalent, understanding more about the early effects of T2DM on cognition may provide insights into the lifetime risks of this disease.
METHODS: In 2016, 186 Australian Aboriginal and/or Torres Strait Islander residents of the Torres Strait (54% female, mean age =38.9 years, SD =15.9, range =15-74) participated in a community health check. The effect of diabetes (Type 1 or Type 2) on speed of thinking and working memory was assessed with the Cogstate Brief Battery (CBB) during the health check.
RESULTS: One third of participants had diabetes (n = 56, 30.1%). After adjusting for age, education and previous iPad/Tablet experience, participants with diabetes had a small, yet significant reduction in accuracy on the One Back working memory task (β = -.076, p = .010, r2  = .042). The effect was most pronounced among participants with diabetes aged 20-49 years (n = 20), who also had evidence of poorer diabetes control (eg HbA1c% ≥6.5, 76.6%), relative to participants with diabetes aged 50 years and over (n = 31) (HbA1c% ≥6.5, 32.0%, p = .005).
CONCLUSIONS: Early and subtle decrements in working memory may be a potential complication of diabetes among Aboriginal and Torres Strait Islander residents of the Torres Strait. Several potentially influential variables were not captured in this study (eg medication and diabetes duration). Greater preventative health resources are required for this population, particularly given the emerging elevated dementia rates linked to chronic disease.
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cognition; complications of diabetes mellitus; indigenous peoples

Mesh:

Year:  2021        PMID: 34559471      PMCID: PMC8754245          DOI: 10.1002/edm2.297

Source DB:  PubMed          Journal:  Endocrinol Diabetes Metab        ISSN: 2398-9238


INTRODUCTION

Type 2 Diabetes (T2DM) is a major global public health concern. In 2017, T2DM was the ninth leading cause of mortality and affected 6.38% of the world's population. This represents a prevalence milestone in a rising trend that shows no signs of abating. In Australia, T2DM was the 12th largest contributor to the country's 2015 burden of disease and affected 5.3% of adults in 2017–2018. Among Aboriginal and Torres Strait Islander inhabitants of Australia, referred to here respectfully as Indigenous Australians, the rate of T2DM is 4.3 times higher than in the non‐Indigenous population. For individuals, T2DM is associated with irreparable damage to multiple body organs and systems, including the brain. For older adults, it is well established that a history of T2DM is associated with a greater likelihood of cognitive impairment and an increased risk for dementia from both cerebrovascular disease and Alzheimer's Disease. In adults without dementia, cognitive impairment associated with T2DM is subtle and expressed most reliably as decreases in processing speed, although this may extend to executive function and working memory. While studies examining T2DM have been conducted mainly in older adults, qualitatively similar but quantitatively less severe cognitive impairment has been observed in adults with T2DM aged less than 60 years. , For Indigenous Australians, the prevalence of dementia is 3–5 times higher than non‐Indigenous Australians. , , , Elevated levels of childhood trauma, stroke, head injury, and lower levels of skilled employment have been identified as predictors of dementia among mainland Aboriginal populations, while more education has been identified as protective. Recent evidence suggests that vascular risk factors, including diabetes, may be associated with higher rates of dementia among Indigenous Australians living in the Torres Strait. , Understanding more about the cognitive implications of diabetes in these vulnerable populations could therefore improve understanding of the development of diabetes‐related brain disease and assist with targeting preventative health activities. The Zenadth Kes Health Partnership (ZKHP) was a community‐based health‐screening program of residents aged 15–78 years, undertaken on two islands in the Torres Strait between October and December 2016. In this population, where diabetes incidence is almost four times the general Australian population, the purpose of the ZKHP was to provide a health service for the community and simultaneously explore the association between the metabolic syndrome and other chronic health conditions. The aim of this current study was to understand whether diabetes, defined as either Type 1 or Type 2, was having a subclinical effect on cognition in this population. It was hypothesized that speed and accuracy on cognitive tasks would reduce as a function of age and increase with years of education and iPad/Tablet experience. It was also hypothesized that participants with diabetes would have slower reaction times and lower accuracy on cognitive tasks, after accounting for age, education and iPad/Tablet experience.

METHODS

Detailed information about the ZKHP methodology is published elsewhere. , A brief overview is provided below. Ethical approval for this study was granted by the Far North Queensland Human Research Ethics Committee (HREC/16/QCH/70–1059).

Participants

Participants were community members aged 15 years and over who identified as being of Torres Strait Islander or Aboriginal descent. A total of 214 participants were screened and met the inclusion criteria (ie consent for both the health check and for the additional research measures). A subset of 14 people met one or more of the exclusion criteria (ie (1) non‐consent, (2) insufficient responses to broader study questions, (3) time constraints or (4) having a physical or sensory disability (eg vision) preventing valid assessment. A total of 200 participants underwent cognitive assessment and the sample for the current study was limited to the 186 participants who had a complete and valid result on at least one of the cognitive tests. The 14 participants excluded at this stage were older than those who were retained (ie mean age of 62.8 and 38.9 years, respectively, p < .001) and more likely to have diabetes (p = .002).

Data collection

Demographic information, diet, health behaviours, depressive symptoms and blood samples for several routine and research blood tests were collected. Demographic data were age (years), gender (male, female), total years of education, employment status when of working age (15–64 years) defined as a person having a paid job (yes, no) and island of residence. Information on history of use of electronic devices (iPad or computer tablet (yes, no)) and hand dominance was also collected. Self‐reported use of alcohol and tobacco was collected, and participants also completed a food questionnaire, which included consumption of take‐away food and sugary drinks in the week preceding their health check. Measures of cardiovascular health included heart rate, systolic and diastolic blood pressure, hypertension (ie systolic ≥140 mmHg or diastolic ≥90 mmHg) and urinary albumin creatinine ratio (urinary ACR). Metabolic markers were triglycerides, high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), total cholesterol, HDL/total cholesterol ratio, glucose, glycosylated haemoglobin (HbA1c%), body mass index (BMI), waist circumference (centimetres), waist/height ratio. Glucose, triglycerides, lipoproteins and cholesterol were analysed at a commercial pathology service (Sullivan Nicolaides, Cairns, Australia). A measure of omega‐3 (n − 3) long‐chain polyunsaturated fatty acid (LCPUFAs) was obtained by a whole blood collection on a validated dried blood spot system. Fatty acid composition was analysed by capillary gas chromatography. An adapted Patient Health Questionnaire 9 (aPHQ‐9) depression screening tool was used to measure depressive symptoms. This instrument has been specifically designed for use with Indigenous Australians in primary healthcare settings.

Diabetes

Participants were defined as having diabetes if they self‐reported being treated for diabetes or had a HbA1c greater than or equal to 6.5% based on blood pathology analyses. The definition of diabetes used in this study encompassed both Type 1 and Type 2. The presence of gestational diabetes (GDM) was not captured. However, given that T2DM is highly prevalent in this population, it likely accounted for almost all of the diabetes cases. Participants who did not report being treated for diabetes and had a HbA1c ≥ 6.5% were considered as ‘newly diagnosed diabetes’. Information on which medication participants with diabetes had been prescribed was obtained by reviewing participant medical records. Collection of this data was limited to participants from only one of the island sites. As a result, medication information was available for approximately half of the participants with diabetes and was not included in the analyses.

Cognitive assessment

Cognition was assessed in the study using the Cogstate Brief Battery (CBB), using an iPad platform, predominantly by a member of the team who was a provisional psychologist (FT). The CBB was selected as the cognitive screening tool as it has high sensitivity to cognitive dysfunction associated with dementia and MCI. The tool also has some usability, acceptability and validity among Indigenous Australians, , , including Indigenous residents of the Torres Strait. Further details on the appropriateness of the CBB and its administration during the current study are described elsewhere. A description of the four CBB tasks and their ‘built‐in’ Completion and Integrity Criteria is provided in Table S1. In brief, the four tasks comprise; (1) Detection, (2) Identification, which are both measures of attention and processing speed, (3) One Card Learning, a measure of visual memory and (4) One Back Learning, a visual measure of working memory. A CBB task was considered ‘complete and valid’ if the task was completed and the results were valid based on examiner observations and Cogstate Integrity Criteria.

Outcome measures

The primary outcome measures in this study were reaction time and accuracy on the CBB tasks. The Detection, Identification and One Back tasks provided three measures of reaction time in milliseconds and log10 transformed milliseconds. The One Card Learning and One Back tasks provided two measures of accuracy as a percentage and an Arcsine transformed percentage. In addition, each participant had a z‐score derived for each of these transformed measures, using normative data in provided by Cogstate PTY LTD. The normative data comprised means and standard deviations for the four CBB tasks for males and females combined by six age groups (18–34, 35–49, 50–59, 60–69, 70–79 and 80–89). Z‐scores that were one standard deviation (SD) below the respective Cogstate mean were flagged using binary yes/no variable (ie z‐score < 1SD), as were z‐score that were two SDs below the mean (ie z‐score < 2SD). In addition, scores that were 0.5 SD below the mean were also flagged, as this cut‐off has been used elsewhere as a more sensitive measure of cognitive impairment. For each participant, a ‘cognitive speed’ domain was derived (ie an average log‐transformed reaction time measure from three tasks with reaction time measures). Similarly, an average Arcsine transformed accuracy measure was derived for each participant from the two tasks with accuracy measures. Only participants with complete and valid measures on these tasks had the average measures derived.

Statistical analyses

All analyses were undertaken using STATA 15 Statistical software (StataCorp. 2017, College Station, TX). Prior to statistical analysis, the distribution of the data was assessed for normality assumptions and outliers. The distribution of study variables (eg demographic and cardio‐metabolic) by diabetes status was tested with independent‐sample t tests and rank‐sum tests for parametric and non‐parametric continuous data, respectively, and with Chi2 tests for categorical data (Table S2). For the CBB outcome variables, the distribution of parametric measures (ie log‐transformed reaction times and Arcsine transformed accuracy) was examined by diabetes status using means and linear regressions (Table S3). Nonparametric CBB outcomes (ie untransformed reaction time and accuracy measures, number of errors and continuous z‐scores) were examined by diabetes status using medians and Wilcoxon rank‐sum tests. Binary variables that identified whether a Z‐score was one or two standard deviations below a Cogstate mean were examined by diabetes status using proportions and Pearson chi‐squared tests. Univariate regression analyses were used to examine the distribution of CBB outcome variables by study variables (eg demographic, cardio‐metabolic and immune markers; Table 1). As age, education and iPad/Tablet experience were all associated with CBB outcomes and diabetes status at a univariate level, these factors were adjusted for in three multivariate regression models examining the relationship between diabetes and each CBB outcome (Table 2). Specifically, Model 1—unadjusted, Model 2—adjusted for age, Model 3—adjusted for age and education, Model 4—adjusted for age, education and previous iPad/Tablet use. Effect size for the regression models was calculated using STATA’s ‘estat esize’ post hoc command. The distribution in One Back Arcsine transformed accuracy measures with confidence intervals, by different age groups (ie 10‐year age groups and three broader age groups) and diabetes status, is provided in Figure 1 and Figure S1. Interaction terms were used to analyse the effect of diabetes on One Back outcomes, within each of these age groups, unadjusted and adjusted for education and previous iPad/Tablet use. p Values < 0.05 were considered statistically significant.
TABLE 1

Performance on selected Cogstate Brief Battery tasks by selected study variables, among 186 Torres Strait Islanders who attended the 2016 Zenadth Kes Health Partnership health screen and completed a Cogstate Brief Battery task.

VariableValuesDetection SpeedIdentification SpeedOne Back Accuracy
N Mean(95%CI) b p N Mean(95% CI) b p N Mean(95% CI) b p
Demographic Information183181169
Age(years)0.0020.0000.0020.000−0.0010.178
GenderMale842.54(2.52,2.56)792.71(2.69,2.72)731.32(1.29,1.36)
Female992.52(2.51,2.54)−0.0130.3411022.69(2.68,2.70)−0.0190.051961.33(1.30,1.36)0.0080.729
Highest educationSome primary82.63(2.46,2.80)92.77(2.68,2.86)61.31(1.23,1.40)
Some secondary562.54(2.52,2.57)−0.0860.014542.70(2.69,2.72)−0.0630.004521.32(1.28,1.36)0.0030.964
Secondary602.51(2.49,2.53)−0.1190.001592.68(2.66,2.69)−0.0890.000541.32(1.28,1.36)0.0070.914
Tertiary572.53(2.50,2.55)−0.1020.004582.69(2.68,2.71)−0.0730.001561.35(1.31,1.39)0.0390.544
Anthropometry
Body Mass Index(kg/m2)0.0000.6210.0010.182−0.0020.202
Waist circumference(cm)0.0010.1890.0010.001−0.0010.062
Waist/Height ratio0.0840.1820.1300.002−0.2070.046
Cardio‐metabolic profile
HbA1c (%)≥6.5232.58(2.52,2.64)232.70(2.68,2.73)211.29(1.22,1.37)
<6.51352.53(2.51,2.54)−0.0520.0161322.69(2.68,2.70)−0.0120.4151241.33(1.30,1.36)0.0380.295
DiabetesNo1292.52(2.50,2.53)1252.69(2.68,2.70)1181.35(1.32,1.38)
Yes542.56(2.53,2.59)0.0410.007562.72(2.70,2.73)0.0300.004511.28(1.24,1.32)−0.0730.003
HypertensionNo1432.52(2.51,2.54)1392.69(2.68,2.70)1331.34(1.31,1.36)
Yes392.55(2.52,2.59)0.0300.077412.71(2.69,2.74)0.0240.032351.31(1.25,1.36)−0.0300.298
Cholesterol/HDL ratio a 0.0–4.51062.53(2.51,2.55)1022.69(2.68,2.70)991.34(1.31,1.37)
>4.5602.54(2.51,2.56)0.0090.579612.70(2.69,2.72)0.0130.190541.29(1.25,1.33)−0.0500.048
Other factors
Used iPad/TabletNo462.57(2.53,2.60)462.72(2.70,2.74)381.30(1.25,1.36)
Yes1362.52(2.50,2.53)−0.0480.0031352.69(2.68,2.70)−0.0270.0131311.34(1.31,1.36)0.0310.259
Omega 3 Index0.0090.1280.0120.001−0.0030.753

Ratio of Total Cholesterol and High‐Density Lipoprotein (HDL) cholesterol.

TABLE 2

Multivariate Regression models of selected Cogstate Brief Battery tasks by selected study variables, among 186 Torres Strait Islanders who attended the 2016 Zenadth Kes Health Partnership health screen and completed a Cogstate Brief Battery task.

VariableValuesDetection SpeedIdentification SpeedOne Back Accuracy
Model 1Model 4Model 1Model 4Model 1Model 4
b a p a b a p a b a p a b a p a b a p a b a p a
DiabetesNo
Yes0.0410.0070.0130.4360.0300.0040.0020.836−0.0730.003−0.0760.010
Demographic Information
Age(years)0.0020.0000.0020.0020.0020.0000.0020.000−0.0010.1780.0000.889
EducationSome secondary (reference)
Secondary−0.0440.009−0.0440.005−0.0350.002−0.0330.0020.0040.8790.0090.762
Tertiary−0.0270.116−0.0390.017−0.0190.105−0.0290.0070.0370.1940.0500.078
iPad/TabletNo (ref)
Yes−0.0480.003−0.0270.013−0.0030.7620.0310.2590.0080.791
Other measures
Body Mass Index(kg/m2)0.0000.621−0.0010.2160.0010.1820.0010.386−0.0020.202−0.0010.776
Waist/Height ratio0.0840.182−0.0270.6830.1300.0020.0630.131−0.2070.046−0.0840.483
HbA1c (%)0.0130.0070.0060.2850.0070.0300.0030.364−0.0050.5310.0080.451
HypertensionNo (reference)
Yes0.0300.0770.0060.7240.0240.0320.0060.560−0.0300.298−0.0190.527
Total Chol/HDL ratio b −0.0020.7910.0000.9760.0030.4740.0030.342−0.0170.080−0.0190.055
Omega 3Index0.0090.128−0.0060.3060.0120.0010.0030.489−0.0030.7530.0140.196
HandednessLeft (reference)
Right−0.0710.003−0.0680.003−0.0150.370−0.0170.262−0.0220.599−0.0370.393
aPHQ Referred c No (reference)
Yes0.0070.7550.0350.126−0.0100.5250.0100.4630.0230.5550.0070.871

Model 1—Unadjusted univariate regression, Model 4—Adjusted for age, education and previous iPad/Tablet experience. Models 2 and 3 are not displayed in this table.

Beta coefficient.

p‐value.

Ratio of Total Cholesterol and High‐Density, Lipoprotein (HDL) cholesterol.

Adapted Patient Health Questionnaire 9.

FIGURE 1

Arcsine transformed proportion of correct responses to the Cogstate Brief Battery One Back working memory test with 95% confidence intervals, by 10‐year age group (Figure 1A) and three age groups (Figure 1B) by diabetes status with number of participants displayed, among Torres Strait Islanders attending the 2016 Zenadth Kes Health Partnership health screen.

Performance on selected Cogstate Brief Battery tasks by selected study variables, among 186 Torres Strait Islanders who attended the 2016 Zenadth Kes Health Partnership health screen and completed a Cogstate Brief Battery task. Ratio of Total Cholesterol and High‐Density Lipoprotein (HDL) cholesterol. Multivariate Regression models of selected Cogstate Brief Battery tasks by selected study variables, among 186 Torres Strait Islanders who attended the 2016 Zenadth Kes Health Partnership health screen and completed a Cogstate Brief Battery task. Model 1—Unadjusted univariate regression, Model 4—Adjusted for age, education and previous iPad/Tablet experience. Models 2 and 3 are not displayed in this table. Beta coefficient. p‐value. Ratio of Total Cholesterol and High‐Density, Lipoprotein (HDL) cholesterol. Adapted Patient Health Questionnaire 9. Arcsine transformed proportion of correct responses to the Cogstate Brief Battery One Back working memory test with 95% confidence intervals, by 10‐year age group (Figure 1A) and three age groups (Figure 1B) by diabetes status with number of participants displayed, among Torres Strait Islanders attending the 2016 Zenadth Kes Health Partnership health screen.

RESULTS

There were 186 participants (54% female, mean age = 38.9 years, SD = 15.9, range = 15–74). Approximately one third (n = 56, 30.1%) had diabetes (Table S1), either as an existing condition (n = 49) or newly diagnosed (n = 7) at assessment. Compared to people without diabetes, those with diabetes were approximately 17 years older (p < .001), more likely to have tertiary education (40.0% and 28.7%, respectively, p = .015), had higher BMI (M = 34.6 and 30.6, respectively, p < .001), greater waist/height ratio (M = 0.70 and 0.61, respectively, p < .001), higher urinary ACR (Table S2), and less likely to have previous iPad/Tablet experience (60.7%) than those without (79.8%, p = .006). The number of CBB tasks completed was equivalent between the groups.

Univariate analyses

When performance on CBB tasks was examined in univariate analyses, participants with diabetes were significantly slower on all reaction time measures and had significantly lower accuracy on the One Back task (Table 1). Reaction times on the three measures increased as a function of age and decreased with years of education. Previous experience with an iPad/Tablet was associated with faster response times. Accuracy on One Card Learning task was not related to any study variables and these results are not tabled.

Multivariate analyses

After adjusting for age, education and previous iPad/Tablet experience (Model 4), none of the three reaction time measures were significantly associated with diabetes status (Table 2) and neither was the derived ‘cognitive speed’ domain (data not tabled). Participants with diabetes had significantly lower accuracy on the One Back task after adjusting for age, education and previous iPad/Tablet experience (Model 4). Post hoc effect size estimates showed diabetes accounted for approximately 4% of the variance in One Back accuracy in this model. As shown in Table S3, the median number of errors on the One Back task was higher in the diabetes group compared to the no diabetes group (3 and 2, respectively, p = .008) and the median z‐score for accuracy on the One Back task was lower among participants with diabetes (−0.39 and 0.09, respectively, p = .002). The proportion of participants with a z‐score ≤ 0.05 standard deviations below the age normative mean was also higher among people with diabetes (47.1% and 30.2%, respectively, p = .039; Table S3). There were no significant differences in z‐score measures on the other tasks. Other cardiovascular risk factors, HbA1c, health behaviours, depression and gender were not related to Cogstate outcomes during univariate and/or multivariate modelling (Table 2). Figure 1 shows the Arcsine transformed proportion of correct responses by diabetes status and age group on the One Back working memory task. Younger participants with diabetes tended to perform worse than participants without diabetes in all age groups up to 50 years. From 50 years of age onward, the accuracy was comparable irrespective of diabetes status. The same trend was evident when average One Back Accuracy z‐scores were graphed by age groups (Figure S1). Multiple regression analyses of One Back accuracy with interaction terms for diabetes and the different age groupings were used to further examine the trends in Figure 1. After adjustment for education and iPad/Tablet experience, there were significant associations in the 20–29, 30–39 and 40–49 age groups, albeit with wide confidence intervals and small cell sizes, compared to the reference group 50 years and over (data not tabled). A post hoc power calculation using G*Power software indicated these analyses were underpowered (ie 1‐β = 68.7%). Using three age groups instead, there was a significant association in the 20–49 year age group (β = −.16, 95% CI: −0.27, −0.05, p = .005) and a post hoc power calculation was adequate (ie >80%). This suggests the effect of diabetes on One Back accuracy in this younger age group was significantly different compared to the reference group 50 years and over (data not tabled). Other interaction analyses were not significant. Table 3 shows younger participants with diabetes (ie 20–49 years, n = 21) had higher levels of morbidity compared to older participants with diabetes (ie 50+ years, n = 31). Specifically, younger participants with diabetes were more likely to be current smokers (65% and 9.7%, respectively, p < .001) and to have consumed a sugary drink in the preceding week (80.0% and 38.7%, respectively, p = .004). They were also more likely to be newly diagnosed with diabetes (25.0% and 6.4%, respectively), have a HbA1c greater than 6.5% (76.5% and 32.0%, respectively, p = .005) and have a higher Total/HDL ratio (4.82 and 3.85, respectively p = .011).
TABLE 3

Comparison of Zenadth Kes Health Partnership participants with diabetes who completed the One Back Cogstate Brief Battery task, by age group, 2016 (n = 51).

VariableValuesDiabetes (20–49 years old)Diabetes (50+years) p
No.(%),mean(95% CI)No.(%),mean(95% CI)
DemographicsTotal2031
GenderFemale13(65.0)(43.6, 86.4)20(64.5)(47.3, 81.8).972
EducationAt least some primary(0.0, 0.0)4(12.9)(0.8, 25.0).374
Some secondary4(21.1)(2.3, 39.8)5(16.1)(2.9, 29.4)
Completed secondary7(36.8)(14.6, 59.1)8(25.8)(10.0, 41.6)
Tertiary8(42.1)(19.3, 64.9)14(45.2)(27.2, 63.1)
Risk BehavioursConsumes alcohol15(75.0)(55.6, 94.4)16(51.6)(33.6, 69.6).095
SmokerNever2(10.0)(−3.5, 23.5)10(32.3)(15.4, 49.1).000
Former5(25.0)(5.6, 44.4)18(58.1)(40.3, 75.9)
Current13(65.0)(43.6, 86.4)3(9.7)(−1.0, 20.3)
Takeaway (prev. week)7(35.0)(13.6, 56.4)9(29.0)(12.7, 45.4).654
Sugary drink yesterday16(80.0)(62.0, 98.0)12(38.7)(21.1, 56.3).004
AnthropometryBody Mass Index (h/kg2)2034.78(31.9, 37.6)3135.45(33.5, 37.4).682
Waist/Height ratio200.69(0.6, 0.7)300.71(0.7, 0.7).221
Cardio‐metabolicHbA1c (%) ≥6.513(76.5)(55.7, 97.2)8(32.0)(13.2, 50.8).005
Hypertension5(26.3)(6.0, 46.6)10(32.3)(15.4, 49.1).656
Total Cholesterol184.93(4.4, 5.5)274.38(4.0, 4.8).087
HDL Cholesterol d 181.09(0.9, 1.2)271.21(1.0, 1.4).144
LDL Cholesterol a 172.64(2.2, 3.1)272.33(2.0, 2.7).255
Total/HDL Ratio b 184.82(4.0, 5.6)273.85(3.4, 4.3).011
Omega 3 Index205.94(5.4, 6.4)317.06(6.6, 7.6).001
Other factorsaPHQ (referred) c 2(10.0)(−3.5, 23.5)1(3.2)(−3.1, 9.6).315
Used iPad/Tablet14(70.0)(49.4, 90.6)18(58.1)(40.3, 75.9).389
ONB Accuracy ‐ Trans.20(1.2)(1.2, 1.3)31(1.3)(1.3, 1.4).105

High‐Density Lipoprotein (HDL).

Low‐Density Lipoprotein (LDL) cholesterol.

Ratio of Total Cholesterol and HDL cholesterol.

Adapted Patient Health Questionnaire 9.

Comparison of Zenadth Kes Health Partnership participants with diabetes who completed the One Back Cogstate Brief Battery task, by age group, 2016 (n = 51). High‐Density Lipoprotein (HDL). Low‐Density Lipoprotein (LDL) cholesterol. Ratio of Total Cholesterol and HDL cholesterol. Adapted Patient Health Questionnaire 9.

DISCUSSION

This study examined relationships between diabetes and cognition, measured by the speed and accuracy of performance on a standardized test battery, in Indigenous Australians living in the Torres Strait. After accounting for age, education and previous iPad/Tablet experience, participants with diabetes had significantly lower accuracy on a task of working memory compared to those without, although the absolute difference between the groups and effect size was both very small. Younger participants (ie 20–49 years of age) with diabetes had lower accuracy scores on this task and evidence of greater morbidity compared to participants 50 years and older with diabetes. As hypothesized, age, education and iPad/Tablet experience were associated with reaction time measures for all participants. There were no differences in speed measures between the participants with and without diabetes after adjusting for these variables. The One Back task used in the current study is a measure of working memory, which is a cognitive ability underpinned by executive functioning. Our results therefore correspond with research showing lower working memory and executive function , among people with T2DM. As the reduction we observed was primarily among participants in their young to mid‐adult life (ie 20–49 years), our results are most consistent with findings from a recent meta‐analysis of 12 studies that showed working memory and executive functioning decrements are observable in midlife among people with T2DM. Our study supports a growing consensus that cognition may be affected in early to mid‐adulthood during T2DM and adds to existing knowledge by showing this may represent a potential complication of diabetes for Indigenous residents of the Torres Strait. The magnitude of reduction observed in One Back accuracy was much lower than reported elsewhere. For example, while Pelimanni and Jehkonen reported medium effect sizes, in our study, the effect was small. Diabetes status accounted for approximately 4% of the variance in One Back performance and participants with diabetes made, on average, one additional error on this task compared to participants without diabetes. This very modest reduction in performance would be considered, at most, a “diabetes associated cognitive decrement”. These are subtle decrements that may give rise to self‐reported complaints, but are unlikely to affect social or occupational functioning or diabetes self‐management. These decrements have been noted to progress slowly over many years, , particularly in the context of chronically elevated blood glucose. , While this may eventually lead to deficits that are clinically or practically important for everyday functioning, it remains unclear whether dementia represents an ‘end point’ on the same continuum. Among older Indigenous residents of the Torres Strait, vascular risk factors such as diabetes have been identified as potential drivers of the elevated dementia rates. The results of the current study may provide some evidence of the detrimental effect of a vascular risk early in this process. However, this proposition remains far from conclusive given the small effect size in our study and the broader uncertainty about the continuum between diabetes‐associated cognitive decrements and later dementia. The difference in One Back accuracy between participants with and without diabetes was most evident in younger age groups and became less pronounced with older age. There may be several study design reasons for this finding. First, Indigenous Australians have an earlier age of mortality, which has resulted in a healthy survivor effect in other research. , In our study, older participants with diabetes were relatively healthy compared to their younger diabetes counterparts in terms of cardio‐metabolic indicators. Our results suggest a healthy survivor effect could extend to cognition, at least in terms of working memory. Our results may have also been influenced by selection bias, where older residents with diabetes and cognitive difficulties may have been less likely to self‐select into a community health screen initially. We also excluded data from 14 participants who were unable to complete any of the CBB tasks, most of whom were older and had diabetes. Had these participants been retained and appropriately supported to undertake the CBB tasks, as noted elsewhere, then poorer performance on the One Back task among people with diabetes may have also been observed in the older age groups. In addition to study design factors, the lower performance of younger participants with diabetes on the One Back task may reflect their increased morbidity relative to their older counterparts. Poorer glycaemic control in the younger group, as evidenced by higher HbA1c, was particularly evident. A systematic review of 86 articles indicated that high HbA1c had a weak negative association with cognitive function in older people (ie 51–85 years of age) with T2DM without dementia. Our study adds to the body of knowledge by suggesting this effect may also be present among younger people who have both diabetes and notable indicators of morbidity. Our limited sample size of 51 people with diabetes, unfortunately, prevented us from exploring this with further modelling. In contrast to many studies, we found no difference in processing speed, as measured by the Detection and Identification tasks, by diabetes status. The requirements of the CBB tasks may be a reason for these contrary results. While these tasks have criterion validity with traditional measures of processing speed, such as the Symbol Digit Modality Test (SDMT) and Grooved Pegboard, there are notable differences. For example, the CBB speed measures lack an ‘executive function’ component, which is present in the SDMT, in the form of working memory and associative learning memory. The CBB measures also have a relatively minor ‘motor’ component, which is a notable domain measured by the Grooved Pegboard test. Further research would be required to examine this possibility. In the absence of this evidence, the current results suggest the CBB tasks are unlikely to be appropriate to detect the early processing speed decrements often seen in diabetes. In terms of strengths, the examiner was blinded to the diabetes status of participants, which reduced the chance of assessment bias. We obtained diabetes status from both self‐report and HbA1c measures. The results of this study suggest that targeted education for younger people with diabetes and improved diabetes monitoring and management may be valuable in terms of protecting later cognitive health, particularly in contexts where there are higher rates of dementia linked to chronic disease. To our knowledge, this is the first study to indicate a detrimental effect of diabetes using a brief computer‐based cognitive screen. Further research in other communities would be required to verify these early findings. There were several study limitations. As noted, the high likelihood of selection bias would mean the sample might not be representative of diabetes and cognition in older age groups. Results from other studies suggest diabetes control, evidenced by HbA1c levels, is associated with cognition in older age groups. Due to small numbers in the older age group, we could not examine the effect of diabetes control in these older ages. Our study also had limited information about medication prescribing and no information about adherence. Year of diagnosis with diabetes was only available in a handful of cases. Duration of diabetes is important, as time with the disease increases risk of cognitive impairment. The small sample size reduced our confidence in regression modelling with interaction terms for multiple age groups. While aggregating participants into three age groups improved this modelling, it prevented examining differences between the younger age groups. This study also did not differentiate by diabetes into Type 1 and 2 Diabetes and GDM. However, given that T2DM is particularly prevalent in this population, it is likely this accounted for most of the diabetes cases.

CONCLUSIONS

In a global context where diabetes remains an important risk factor for cognitive decline, our findings suggest that early and subtle decrements in working memory may be a potential complication of diabetes among Indigenous Australians living in the Torres Strait. In this population, which has elevated dementia rates linked to chronic disease, our results highlight the need for more preventative health resourcing. Our results suggest that early identification of younger people with diabetes, targeted education and supported glycaemic control could be important for protecting cognitive health.

CONFLICT OF INTEREST

P.M. is a full‐time employee of CogState Ltd. CogState Ltd. provided the CogState tasks reported in this study. The remaining authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Fintan Thompson: Data curation (Lead); Formal analysis (Lead); Investigation (Supporting); Methodology (Equal); Writing‐original draft (lead); Writing‐review & editing (lead). Linton R. Harriss: Investigation (equal); Methodology (equal); Project administration (equal); Writing‐original draft (supporting); Writing‐review & editing (supporting). Sarah Russell: Formal analysis (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Sean Taylor: Conceptualization (equal); Investigation (equal); Methodology (equal); Project administration (equal); Writing‐original draft (supporting). Lucette A. Cysique: Formal analysis (supporting); Methodology (supporting); Resources (supporting); Software (supporting); Writing‐original draft (supporting). Edward Strivens: Writing‐original draft (supporting); Writing‐review & editing (supporting). Paul Maruff: Methodology (supporting); Resources (supporting); Software (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Robyn McDermott: Conceptualization (lead); Funding acquisition (lead); Investigation (lead); Methodology (lead); Project administration (lead); Resources (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Fig S1 Click here for additional data file. Table S1‐S3 Click here for additional data file.
  33 in total

1.  Type 2 Diabetes and Cognitive Functions in Middle Age: A Meta-Analysis.

Authors:  Elina Pelimanni; Mervi Jehkonen
Journal:  J Int Neuropsychol Soc       Date:  2018-12-21       Impact factor: 2.892

2.  Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging.

Authors:  Michelle M Mielke; Stephen D Weigand; Heather J Wiste; Prashanthi Vemuri; Mary M Machulda; Davis S Knopman; Val Lowe; Rosebud O Roberts; Kejal Kantarci; Walter A Rocca; Clifford R Jack; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2014-11-15       Impact factor: 21.566

3.  Prevalence of dementia in the Torres Strait.

Authors:  Sarah G Russell; Rachel Quigley; Fintan Thompson; Betty Sagigi; Dina LoGiudice; Kate Smith; Nancy Pachana; Gavin Miller; Edward Strivens
Journal:  Australas J Ageing       Date:  2020-11-10       Impact factor: 2.111

Review 4.  Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus--a review with implications for future intervention studies.

Authors:  Rachel Heloise Xiwen Wong; Andrew Scholey; Peter Ranald Charles Howe
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

5.  A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application.

Authors:  Ge Liu; Beverly Sara Mühlhäusler; Robert Alan Gibson
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-09-30       Impact factor: 4.006

6.  Dementia prevalence and incidence among the Indigenous and non-Indigenous populations of the Northern Territory.

Authors:  Shu Qin Li; Steven L Guthridge; Padmasiri Eswara Aratchige; Michael P Lowe; Zhiqiang Wang; Yuejen Zhao; Vicki Krause
Journal:  Med J Aust       Date:  2014-05-05       Impact factor: 7.738

7.  Long-term trends in cancer mortality for Indigenous Australians in the Northern Territory.

Authors:  John R Condon; Tony Barnes; Joan Cunningham; Bruce K Armstrong
Journal:  Med J Aust       Date:  2004-05-17       Impact factor: 7.738

8.  Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease.

Authors:  Paul Maruff; Yen Ying Lim; David Darby; Kathryn A Ellis; Robert H Pietrzak; Peter J Snyder; Ashley I Bush; Cassandra Szoeke; Adrian Schembri; David Ames; Colin L Masters
Journal:  BMC Psychol       Date:  2013-12-23

Review 9.  Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing.

Authors:  Judith Jaeger
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

10.  Using health check data to investigate cognitive function in Aboriginal and Torres Strait Islanders living with diabetes in the Torres Strait, Australia.

Authors:  Fintan Thompson; Linton R Harriss; Sarah Russell; Sean Taylor; Lucette A Cysique; Edward Strivens; Paul Maruff; Robyn McDermott
Journal:  Endocrinol Diabetes Metab       Date:  2021-09-24
View more
  2 in total

1.  Potentially preventable dementia in a First Nations population in the Torres Strait and Northern Peninsula Area of North Queensland, Australia: A cross sectional analysis using population attributable fractions.

Authors:  Fintan Thompson; Sarah Russell; Rachel Quigley; Betty Sagigi; Sean Taylor; Malcolm McDonald; Sandy Campbell; Adrian Esterman; Linton R Harriss; Gavin Miller; Edward Strivens; Robyn McDermott
Journal:  Lancet Reg Health West Pac       Date:  2022-07-06

2.  Using health check data to investigate cognitive function in Aboriginal and Torres Strait Islanders living with diabetes in the Torres Strait, Australia.

Authors:  Fintan Thompson; Linton R Harriss; Sarah Russell; Sean Taylor; Lucette A Cysique; Edward Strivens; Paul Maruff; Robyn McDermott
Journal:  Endocrinol Diabetes Metab       Date:  2021-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.